首页 > 抗体蛋白 > 抗体
Purified anti-human FOXP3 Antibody
产品名称:
Purified anti-human FOXP3 Antibody
产品类别:
抗体
产品编号:
320101
产品应用:
320101
[价格]
规格 价格 库存
25µg ¥ 1548 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Baboon, Cynomolgus, Rhesus, Pigtailed Macaque
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full-length FOXP3 protein
Formulation
This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

WB - Quality tested
ICFC, IHC-F, IHC-P - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent intracellular staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 ?g per 106 cells in 100 ?l volume. For Western blotting, the suggested working dilution(s) is ≤ 5.0 ?g/ml in antibody dilution buffer. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1 and formalin-fixed paraffin-embedded sections1,8,19-20, and Western blotting1. The binding of 206D to FOXP3 can be partially blocked by 259D, but 206D does not show significant blocking effect on 259D binding.

NOTE: For flow cytometric staining with this clone, True-Nuclear? Transcription Factor Buffer Set (Cat. No. 424401) offers improved staining and is highly recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Roncador G, et al. 2005. Eur. J. Immunol. 35:1681.(IHC)
  2. Yang ZZ, et al. 2006. Blood 107:3639.
  3. Liu W, et al. 2006. J. Exp. Med. 203:1701.PubMed
  4. Bollyky PL, et al. 2007. J. Immunol. 179:744.
  5. Bell MP, et al. 2007. J. Immunol. 179:1893.
  6. Tran DQ, et al. 2007. Blood doi:10.1182/blood-2007-06-094656. PubMed
  7. Gao Q,et al.2007.J Clin Oncol.25:2586.(IHC) PubMed
  8. Pillai V,et al. 2008. Blood 111:463. PubMed
  9. Zheng Y, et al. 2008. J. Immunol. 181:1683. PubMed
  10. Zonios DI, et al. 2008.Blood112:287. PubMed
  11. Kavanagh B, et al. 2008. Blood. PubMed
  12. Nevala WK, et al. 2009. Clin Cancer Res. 15:1931. PubMed
  13. Grant J, et al. 2009. Cytometry B Clin Cytom. 76:69. PubMed
  14. Nigam P, et al. 2010. J. Immunol. 184:1690. PubMed
  15. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (ICFC) PubMed
  16. Hartigan-O'Connor DJ,et al.2007.J Exp Med.204:2679. PubMed
  17. Raghaven S, et al. 2009. Ann Rheum Dis. 68:1908. PubMed
  18. Hodi FS, et al. 2014. Cancer Immunol Res. 2:632.(IHC) PubMed
  19. Sziros E, et al. 2015. Clin Cancer Res. 21:2840.(IHC) PubMed
Product Citations
  1. Chen S, et al. 2020. Transl Lung Cancer Res. 1.404861111. PubMed
  2. Kavanagh B, et al. 2008. Blood. 112:1175. PubMed
  3. Richardson LG, et al. 2020. Oncoimmunology. 9:1806662. PubMed
  4. Riquelme E et al. 2019. Cell. 178(4):795-806 . PubMed
  5. Parra E,et al. 2017. Sci Rep.. 10.1038/s41598-017-13942-8. PubMed
  6. Chen P, et al. 2021. J Immunother Cancer. 9:. PubMed
  7. Haymaker C, et al. 2021. Cancer Discov. 11:1996. PubMed
  8. Nugent JL, et al. 2021. iScience. 24:103421. PubMed
  9. Karandikar V 2008. Blood. 111:463. PubMed
  10. Werneburg S, et al. 2020. Immunity. 52(1):167-182.e7.. PubMed
  11. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  12. Mitra A, et al. 2020. Nat Commun. 11:1839. PubMed
  13. Derks S, et al. 2020. Ann Oncol. 31:1011. PubMed
  14. Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed
  15. Vence L, et al. 2019. Clin Cancer Res. 25:6501. PubMed
  16. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
  17. Burlingame EA, et al. 2021. Cell Rep Methods. 1:. PubMed
  18. Boucher Y, et al. 2021. NPJ Precis Oncol. 5:62. PubMed
  19. de Groot J, et al. 2020. Neuro Oncol. 539:22. PubMed
  20. Helmink BA, et al. 2020. Nature. 577:549. PubMed
  21. Li W, et al. 2018. BMC Cancer. 1.589583333. PubMed
  22. Xie S, et al. 2020. Ann Transl Med. 1.384027778. PubMed
  23. Zeigler-Johnson C, et al. 2016. PLoS One. 11: 0159109. PubMed
  24. Gao Q, et al. 2007. J Clinical Oncololgy. 25:2586. PubMed
  25. Donnelly C, et al. 2018. Sci Rep. 0.625. PubMed
  26. Msaouel P, et al. 2020. Cancer Cell. 720:37. PubMed
  27. Hodi F, et al. 2014. Cancer Immunol Res. 2:632. PubMed
  28. Zsiros E, et al. 2015. Clin Cancer Res. 21:2840. PubMed
  29. Sadigh S, et al. 2020. Am J Clin Pathol. 387:153. PubMed
  30. Wang H, et al. 2021. Onco Targets Ther. 14:2953. PubMed
  31. Luoma AM, et al. 2020. Cell. 182(3):655-671.e22. PubMed
  32. Amaria RN, et al. 2018. Nat Med. 24:1649. PubMed
  33. Blessin NC, et al. 2019. Dis Markers. 2019:5160565. PubMed
  34. Durgin JS, et al. 2021. Front Oncol. 11:669071. PubMed
  35. Jiang M, et al. 2021. J Immunother Cancer. 9:. PubMed
  36. Zonios D, et al. 2008. Blood. 112:287. PubMed
RRID
AB_430880 (BioLegend Cat. No. 320101) AB_430881 (BioLegend Cat. No. 320102)

Antigen Details

Structure
Forkhead/winged-helix transcription factor family, approximately 50 kD, contains zinc finger and forkhead domains
Distribution

Nuclear; expressed in T regulatory cells

Function
Transcription factor proposed to be a master regulatory gene in T regulatory cell development and a critical factor for immune homeostasis
Interaction
Interacts with DNA
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Transcription Factors
Molecular Family
Nuclear Markers
Antigen References

1. Hori S, et al. 2003. Science 299:1057.
2. Gandhi R, et al. 2010. Nat. Immunol. 11:846.

Regulation
FOXP3 is present at high levels in T regulatory cells, it can also be induced by T cell activation.
Gene ID
50943 View all products for this Gene ID
UniProt
View information about FOXP3 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线